Welcome back to the Psychedelic Invest week in review. Here are the stories that moved the psychedelic sector during the week of May 18–24, 2026 — from clinical readouts to regulatory shifts and the capital flowing through the space.
Optimi Health Corp. (OPTH): Optimi Health closes oversubscribed US$15M offering and uplists to Nasdaq
Optimi Health closed an oversubscribed US$15 million underwritten public offering tied to the uplisting of its common shares to the Nasdaq Capital Market, issuing 2.4 million shares at US$6.25 each. The shares began trading on Nasdaq under the ticker OPTH on May 20, 2026, with the offering closing on May 21. The uplisting and fresh capital strengthen the commercial-stage psilocybin manufacturer's access to U.S. investors as it scales exports to Australia and prepares clinical-trial supply.
Source: investingnews.com
GH Research PLC (GHRS): GH Research to present new GH001 Phase 2b data in treatment-resistant depression at ASCP 2026
GH Research said it would present new Phase 2b data on its inhaled 5-MeO-DMT candidate GH001 for treatment-resistant depression at the American Society of Clinical Psychopharmacology (ASCP) annual meeting in Miami. The presentations cover multiple posters from the GH001-TRD-201 study, including efficacy by prior antidepressant failure and effects on anhedonia. The disclosure keeps investor attention on GH001 as the company advances toward a global Phase 3 program in 2026.
Source: tipranks.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.